20-Year Pro Trader Reveals His "MoneyLine"
Ditch your indicators and use the "MoneyLine". A simple line tells you when to buy and sell without the guesswork. It’s a line on a chart that’s helped Nic Chahine win 83% of his options buys. Here's how he does it.
Mesoblast Limited (NASDAQ:MESO) received feedback from the FDA's Office of Tissues and Advanced Therapies (OTAT) on the Phase 3 program of rexlemestrocel-L in patients.
- The trial is assessing rexlemestrocel-L in patients with chronic low back pain (CLBP) due to degenerative disc disease refractory to available therapies, including opioids.
- Mesoblast plans to conduct an additional U.S. Phase 3 trial which may support submissions for potential approval in the U.S. and EU.
- The trial will include at least 20% of subjects from the EU to support global submission plans.
- Following the data review, OTAT agreed with Mesoblast's proposal for pain reduction at 12 months as the primary endpoint of the subsequent trial.
- Functional improvement and reduction in opioid use will be secondary endpoints.
- Suppose this trial is successful and leads to EU regulatory approval. In that case, Mesoblast is eligible to receive up to $112.5 million before the product launch in the EU from its partner in Europe and Latin America, Grünenthal.
- Cumulative milestone payments could reach US$1 billion depending on the outcome of Phase 3 studies.
- Related Link: Why Mesoblast Shares Are Falling
- Price Action: MESO shares are up 5.63% at $5.25 during the premarket session on the last check Thursday.
20-Year Pro Trader Reveals His "MoneyLine"
Ditch your indicators and use the "MoneyLine". A simple line tells you when to buy and sell without the guesswork. It’s a line on a chart that’s helped Nic Chahine win 83% of his options buys. Here's how he does it.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!